Status:
TERMINATED
Minimally Invasive Control of Epistaxis (MICE)
Lead Sponsor:
University of Calgary
Conditions:
Epistaxis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Epistaxis is a common disorder with 60% of the population suffering from one episode and 10% of these cases requiring medical attention. Between March 2006 and March 2007, in Calgary, Alberta, there w...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age ≥ 18 years old, Presenting to Rockyview General Hospital Emergency room
- No coagulopathy (must have INR reversed before inclusion)
- Available for follow-up at 1 week and 1 month in Calgary, Alberta
- Refractory or Recurrent Epistaxis defined as:
- Refractory = unable to control epistaxis with bilateral Merocel™ Nasal Tampons fully inserted into nasal cavity
- Recurrent = epistaxis after removal of Merocel™ Nasal Tampons following outpatient packing for 48 hours
- Exclusion Criteria:
- Uncorrectable coagulopathy
- Unable to comply with procedure
- Pregnancy
- Non-Calgary emergency room presentation
- Severe posterior epistaxis requiring intubation for airway protection
Exclusion
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00666471
Start Date
June 1 2008
End Date
June 1 2009
Last Update
June 12 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rockyview General Hospital / University of Calgary
Calgary, Alberta, Canada